E‐cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora and HSP90 in preclinical models

Corresponding Author

Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

K.G. Jebsen Colorectal Cancer Research Centre, Division for Cancer Medicine, Oslo University Hospital, Oslo, Norway

Corresponding authors

Name: Teijo Pellinen, Address: Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland, Phone: +358 50300 5688

Name: Jarle Bruun, Address: Norwegian Radium Hospital, Montebello, Oslo, Norway, Phone: +47 4123 4614

View original article

0 0 0 0 0 0 0

留言 (0)